Drugs / KH801
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06364501 | Sep 2024 → May 2026 overdue | cancer | Beijing Kanghong Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-03-25 | Chengdu Kanghong Biotech Co., Ltd. | Regulatory 康弘药业自研治疗晚期实体瘤新药获批开展临床试验 cnkh.com ↗
近日，康弘药业子公司北京康弘生物医药有限公司收到国家药品监督管理局的通知，同意KH801注射液开展临床试验。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-03-25 | Chengdu Kanghong Biotech Co., Ltd. | 康弘药业自研治疗晚期实体瘤新药获批开展临床试验 cnkh.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KH801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06364501 ↗ |
| Route | Intravenous | “administered via intravenous infusion” NCT06364501 ↗ |